Baird Initiates Coverage On Amylyx Pharma with Outperform Rating, Announces Price Target of $37
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Joel Beatty has initiated coverage on Amylyx Pharmaceuticals with an Outperform rating and set a price target of $37 for the company's stock.
January 03, 2024 | 10:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baird analyst Joel Beatty initiated coverage on Amylyx Pharmaceuticals with an Outperform rating and a price target of $37, which could positively influence the stock's performance.
The initiation of coverage by Baird with an Outperform rating typically indicates a positive outlook on the stock's future performance. The price target of $37 suggests a significant upside from the current trading price, which can lead to increased investor interest and potentially drive up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100